Insider Selling: Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Sells 10,230 Shares of Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 10,230 shares of Pliant Therapeutics stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total transaction of $112,427.70. Following the completion of the transaction, the general counsel now directly owns 70,544 shares in the company, valued at $775,278.56. This represents a 12.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mike Ouimette also recently made the following trade(s):

• On Friday, January 17th, Mike Ouimette sold 13,270 shares of Pliant Therapeutics stock. The shares were sold at an average price of $11.20, for a total transaction of $148,624.00.

Pliant Therapeutics Price Performance

NASDAQ PLRX opened at $10.92 on Thursday. The firm’s 50 day moving average price is $13.24 and its two-hundred day moving average price is $13.08. Pliant Therapeutics, Inc. has a twelve month low of $10.22 and a twelve month high of $18.92. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.04. As a group, sell-side analysts forecast that Pliant Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of Pliant Therapeutics in a research note on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $40.50.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in Pliant Therapeutics by 27.2% in the 4th quarter. SG Americas Securities LLC now owns 30,729 shares of the company’s stock valued at $405,000 after buying an additional 6,579 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Pliant Therapeutics by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 108,608 shares of the company’s stock worth $1,430,000 after acquiring an additional 16,634 shares during the period. Harbor Capital Advisors Inc. boosted its stake in Pliant Therapeutics by 4.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 95,801 shares of the company’s stock worth $1,262,000 after buying an additional 3,822 shares in the last quarter. Exome Asset Management LLC boosted its position in shares of Pliant Therapeutics by 20.6% during the 3rd quarter. Exome Asset Management LLC now owns 149,600 shares of the company’s stock valued at $1,677,000 after acquiring an additional 25,600 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Pliant Therapeutics by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,039,904 shares of the company’s stock valued at $11,657,000 after acquiring an additional 14,913 shares during the period. Institutional investors and hedge funds own 97.30% of the company’s stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.